For most of the large molecules and bio reagent projects, molecular biology is the starting point which involves construct design, gene synthesis and cloning. In addition to standard molecular biology solutions, we provide specialized services to support target identification, antibody discovery, metabolic engineering and translational research.
Our service range includes:
Recombinant DNA technology Antibody gene sequencing (high-throughput) Mutagenesis Customized Library generation Plasmid DNA preparation & scale-up for CGT requirements Microbial genome engineering Gene expression analysis IVT mRNA synthesis
Recombinant DNA Technology
Cloning and vector generation:
Gene cloning service at Aurigene supports customized generation of recombinant constructs by various methods for generation of antibodies, enzymes, and reagent proteins:
- Ligation dependent and independent cloning
- Recombination based high throughput cloning
- De novo cloning (synthetic gene fragments, PCR, and cDNA based)
- Customized vector construction based on client requirement
Plasmid DNA preparation:
Plasmid DNA purification service caters to both small research facilities as well as large-scale manufacturing for biotech and pharmaceutical companies:
- Research grade plasmid at small scale suitable for cloning, mutagenesis, microbial transformation and protein production
- High-quality industrial grade plasmid suitable for :
- Protein
- Antibody production
- Stable cell line generation in mammalian cells
- Bacmid generation for protein expression in insect cells
- Viral packaging
- In vitro mRNA synthesis
- Vaccine
- Gene therapy studies, and
- Animal immunization
- Process development for customized plasmid propagation and purification
Mutagenesis:
Site-directed mutagenesis service enables life science researchers by creating specific DNA mutations for studying gene regulation, DNA-protein interactions, protein structure or function relationship, enzyme function and novel recombinant proteins:
- Point mutation, insertion, deletion or gene fragment replacement
- Customized mutagenesis requirements such as random and site-directed mutagenesis and mutant library generation
- Gene shuffling, combinatorial mutagenesis, alanine scanning and site saturation mutagenesis
Antibody Gene Sequencing and Reformatting
Antibody sequence information from hybridoma is essential for protection, preservation and optimization of monoclonal antibodies (mAbs). Antibody gene sequencing and reformatting at Aurigene is a one-stop solution for recombinant expression and production of antibodies:
- RACE (Rapid Amplification of cDNA Ends) using template switching adapter ligation
- Degenerate oligos
- De novo antibody sequencing and analysis using LC-MS/MS
- Reformatting antibody gene sequences into various other production formats like bispecifics, mAb, scFv, Fab, F (ab)'2, and VHH or nanobody
- Antibody gene sequencing for mouse, rat, rabbit and other species.
Strain Engineering
Experience in genome scale modification of bacterial and yeast strains for production of recombinant proteins, platform chemicals and metabolic engineering:
- BSL-1 and BSL-2 microbes
- Gene knock out and knock-in using homologous recombination based methods
- Characterization of engineered strains using microbiological methods, RT-PCR and advanced analytics
- CRISPR-Cas9 based mutagenesis
Library Generation and Evaluation
Constructing cDNA libraries, phage libraries and yeast libraries along with provisions for high throughput screening and functional characterization.
Gene expression analysis
Regulation and expression of genes at the transcriptional and translational stages play a crucial role in determining gene function. Scientists at Aurigene carry out routine expression studies by several methods such as:
- Quantitative real time PCR
- ELISA in various formats
- Flow cytometry
- Western blotting
- Mass spectrometry
Residual Protein, DNA and Mycoplasma Detection
Residual host-cell proteins (HCP) and host-cell DNA (HCD) are impurities that remain in recombinant bio therapeutics. We ensure that these impurities and contaminants are detected and reduced to levels below those guided by regulatory agencies:
- Quantitative real-time PCR
- ELISA
- SPR (BIAcore)
- Mycoplasma test
Why Aurigene Pharmaceutical Services?
State-of-the-art facilities with high-end instrumentation
Wide range of tools under one umbrella
Customized generation of recombinant constructs
Fast and innovative solutions
One-stop solution for recombinant expression and production of antibodies
Virtual Tour
Hyderabad R and D Center
Bangalore R and D Center
Contact Us
Resources
JUNE 28, 2022
Neoantigen Specific T cells For Cancer Immunotherapy
Neoantigen specific T cells for cellular cancer immunotherapy An effective anti-tumor immune response in human is marked by presence of T cells reactive against neoantigens. Neoantigens are HLA-bound unique peptides arise from tumor-specific somatic mutations. Neoantigens are highly immunogenic because they are not present in normal tissues and hence...
Read More
Building successful long-term partnerships with CDMOs from early drug discovery through commercialization
Building successful long-term partnerships with CDMOs from early drug discovery through commercialization Maximizing efficiency in drug research, development, and manufacturing is crucial for turning new innovations into therapeutic and financial benefits. Over the past couple of decades, pharmaceutical companies have increasingly turned to contr...
Read More
Technology meets sustainability - How a complex API development process goes green
We are always looking for ways to enhance the sustainability of our products and services. Our team successfully developed a scalable manufacturing process for the API product of one of our Biotech clients using eco-friendly manufacturing technologies. Read the case study to learn more. ...
Read MoreAlternate end-game strategies towards Nirmatrelvir synthesis: Defining a continuous flow process for the preparation of an anti-COVID drug
2023
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...
Read More-
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2021
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More -
Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry
2021
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...
Read More -
Simple and efficient synthesis of imidazoquinoxalines and spiroquinoxalinones via pictect-spengler reaction using Wang resin, Synthetic Communications
2021
An efficient approach for the synthesis of various imidazoquinoxalines and spiroquinoxalinones has been reported from 2-(1H-imidazol-1-yl) aniline and .. ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.